Innventure, Inc.

# Signal Note: Driehaus Capital Entry into Innventure (INVLW) Driehaus Capital's $5.3M initiation suggests conviction in Innventure's inhalation platform and near-term catalysts, likely tied to its lead program INV-2 (nebulized dihydroartemisinin for severe malaria) or pulmonary asset development. The timing aligns with potential clinical readouts or partnerships that could de-risk the early-stage platform. Given Driehaus's growth-focused biotech mandate, this signals confidence in either meaningful efficacy data or commercial validation rather than speculative positioning.